Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.
Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback